In-Silico Analysis of Differentially Expressed Genes and Their Regulating microRNA Involved in Lymph Node Metastasis in Invasive Breast Carcinoma.

Axillary nodal metastasis is related to poor prognosis in breast cancer (BC). Key candidate genes in BC lymph node metastasis have been identified from Gene Expression Omnibus datasets and explored through functional enrichment database for annotation, visualization and integrated discovery (DAVID) , protein-protein interaction by Search Tool for the Retrieval of Interacting Genes and proteins (STRING), network visualization (Cytoscape), survival analysis (GEPIA, KM Plotter), and target prediction (miRNet). A total of 102 overlapping differentially expressed genes were found. In-silico survival and expression analyses revealed six candidate hub genes, Desmocollin 3 (DSC3), KRT5, KRT6B, KRT17, KRT81, and SERPINB5, to be significantly associated with nodal metastasis and overall survival, and 83 MicroRNA (miRNAs), which may be potential diagnostic markers and therapeutic targets in BC patients.

A Combined Analysis of Serum Growth Differentiation Factor-15 and Cancer Antigen 15-3 Enhances the Diagnostic Efficiency in Breast Cancer.

INTRODUCTION: Existing diagnostic biomarkers of breast cancer (BC) are limited by poor sensitivity. In this study, we evaluated the role of serum GDF-15 in early BC diagnosis, independently and in combination with CA15-3, a known blood biomarker of BC. MATERIAL AND METHODS: A total of 113 diagnosed, pre-therapy BC patients and 54 healthy controls were recruited. Clinical characteristics, TNM staging, and hormone receptor status of the patients were recorded. Serum GDF-15 and serum CA15-3 were measured by sandwich ELISA and chemiluminescence assay, respectively. RESULTS: The serum GDF-15 levels were significantly (p<0.001) elevated in BC patients compared to healthy controls and in patients with larger tumor size, advanced disease stage, and distant metastasis. ROC analysis revealed that at the cut-off of 525.77 pg/mL, GDF-15 had greater sensitivity than CA15-3. GDF-15 and CA15-3 performed better in combination than individually, with the combined test having an AUC of 0.85 and sensitivity and specificity of 0.63 and 0.98, respectively.Further, serum GDF-15 had a better predictive ability for early-stage BC compared to CA15-3. GDF-15 could independently diagnose BC patients after adjusting for age. CONCLUSION: We conclude that serum GDF-15 is a promising, robust marker for detecting early-stage BC. However, larger prospective studies are necessary to validate this claim.

Adjuvant Irradiation in Carcinoma Breast Patients: Comparison of 3DCRT and Semi-automated Complex VMAT Hypofractionated Plans.

OBJECTIVE: Adjuvant radiotherapy is required for most post MRM breast cancer patients. Aim of treatment is to target radiation to region of interest while sparing Organs at Risk (OARs). Attempts are being made to decrease dose to OARs without compromising target coverage by evolving radiation techniques. In this study, a comparison of traditional 3DCRT plans is done with semi-automated complex VMAT plans for dose received by OARs namely Contralateral Breast (CLB), Ipsilateral lung (I/LL), and Contralateral Lung (C/LL). MATERIALS AND METHODS: It was planned for 30 post MRM breast cancer patients for chest wall, ipsilateral axilla and supraclavicular lymph node. The PTV dose was 42.5 Gy in 16 fractions, 2.66 Gy/fraction, 5 days a week. For each patient traditional 3DCRT and semi-automated complex VMAT plans (conventional + tangential VMAT plans) were prepared and evaluated by radiation oncologists. RESULTS: Dose evaluation of CLB shows higher Dmax for 3DCRT plans, while, Dmean was lower for the 3DCRT plan. Difference between D2 was not significant. V2.5 was significantly less in 3DCRT, while, difference between V5 and V10 were not significant. For C/LL Dmean, V2.5, V5, and V10 were higher for the VMAT plan. For I/LL Dmean, V5 and V10 were higher, while V20 and V30 were lower for VMAT plans. DISCUSSION AND CONCLUSION: The VMAT technique described here is a useful treatment option available for difficult planning situations. OARs stated above had a mixed result showing VMAT plans to be inferior at lower dose metrics, while, superior at higher dose metrics.